Is Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) a Myth?
Main Article Content
Abstract
The prevalence of Diarrhea Predominant Irritable Bowel Syndrome (IBS D) and chronic diarrhea has been one of the most troublesome diagnoses inflicting approximately 5% of the population annually. These entities have always perplexed physicians that attempt to offer relief to millions of sufferers. Because of the magnitude of the problem, physicians and researchers have been reaching out to further classify and understand these entities. This review will shed some light on current analysis and thinking of IBS-D and offer a challenging new alternative approach in understanding and treatment for this condition. It will indicate that IBS-D is not a true clinical entity in fact, it demonstrates that a more detailed history and clinical work up of patients may indeed lead to a true and treatable clinical diagnosis, highlighting a more significant role of Bile acid abnormalities in the pathogenesis of chronic diarrhea.
Article Details
How to Cite
HABBA, Saad F..
Is Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) a Myth?.
Medical Research Archives, [S.l.], v. 10, n. 8, aug. 2022.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/2975>. Date accessed: 21 nov. 2024.
doi: https://doi.org/10.18103/mra.v10i8.2975.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Saito Y, Schoenfeld P, Locke GR. The epidemiology of I irritable bowel syndrome in North America. A systematic review. Am J Gastroenterol 2002;97: 1910
2. Drossman DA, Corazziari E, Talley NJ, Whitehead WE, Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology, and treatment. A multi-national consensus. 2nd edition. McLean VA Dagnon associates 2000
3. Boyce PM, Koloski NA, Talley NJL. Irritable bowel syndrome according to varying diagnostic criteria. Is the new Rome to criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2009; 95:3176
4. Peery AF, Dellon ES, Lund J, et al, Burden of gastrointestinal disease in the United States 2012 update. Gastroenterology 2012:143:1179
5. Creed F, Ratcliffe J, Fernandez L, et al. Health related quality of life and healthcare costs and severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 860–8
6. Dean BB, Anguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life and patience with IBS. Am J Manag Care 2005:11S17-26
7. Blake MR, Raker JM, Wheelan K, Validity, and reliability of the Bristol stool form scale in healthy adults and patience with diarrhea predominant irritable bowel syndrome. Ailment Pharmacol Ther 2016; 44:693
8. Schiller, L . Am J Gastroenterol 2018; Volume113-issue 5: p660-669
9. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130;1480
10. Mearin F, Lacy BE, Chang L et al. Bowel Disorders Gastroenterology 2016;150:1393-407
11. Ford AC, Lacy BE, Talley NJ, irritable bowel syndrome. N Eng J Med 2017; 376:2566-78
12. Ford AC, Moayyedi P, Lacy BE, et al. American College of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 (Suppl 1): S2-26
13. McKenzi YA, Alder A,Anderson W,et al. Are British dietetic Association evidence-based guidelines for the dietary management of her irritable bowel syndrome in adults. J Hum Nutr Diet 2012; 25:260
14. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms and irritable bowel syndrome. J Gastronterol Hepatol 2010;25:1366
15. Austin GL, Dalton CB,Hu Y, etal. A very low carbohydrate diet improves symptoms and quality of life in diarrhea predominant irritable bowel syndrome. Clin Gastroenterol Heptol 2009; 7:706
16. Rao SS, Yu S, Fedewa A, A systemic review: dietary fiber and FODMAP-restricted are diet in the management of constipation and a double bowel syndrome. Aliment Pharmacol Ther 2015; 41:1256
17. Eswan SL, Chey WD, Han-Markey T, et al. Randomized controlled trial comparing the low FODMAP diet VS modified NICE guidelines in the US adults with IBS D. Am J Gastroenterol 2016;111:1824
18. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012;345: e5836
19. Zighelboim J,Talley NJ, Phillips SF, et al . Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and Serotonin type 3 antagonism. Dig Dis Sci 1995; 40:819
20. Prior A,Read NW. Reduction of rectal sensitivity and post prandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175
21. Grehon MD, Seratonin and its implications for the management of irritable bowel syndrome. Gastroenterol Disord 2003;3 suppl 2: S25
22. Vasquez-Rofque MI, Camilleri M, Smyrk T et al, a controlled trial of gluten-free diet and patience with irritable bowel syndrome diarrhea effects on bowel frequency and intestinal function. Gastroenterology 2013; 144:903
23. Ruepert L,Quartero AO, deWit NJ, et al, bulking agents and antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; CD 003460
24. Gorard DA, LibbyGW, Farthing MJ. Effect of tricyclic antidepressants on small intestinal motility in health and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86
25. Bueno Fioramonti J,Delvaux M et al, Mediators and pharmacology of visceral sensitivity from basic to clinical investigations. Gastroenterology 1997; 1121:1714
26. American College of gastroenterology task force on irritable bowel syndrome. Brandt LJ, Chey WD, et al. An evidence-based position statement on management of irritable bowel syndrome. Am J Gastroenterol 2009;104suppl 1: S1
27. Multicenter randomized controlled trial. Clin Gastroenterol Hepatol 2015; 13:1285
28. Menees SB, Maneerattannaporn M, Kim HM et al. The efficacy and safety of Rifaximin for the irritable bowel syndrome; a systematic review and meta-analysis. Am J Gastroenterol 2012; 107:28
29. Habba SF, Med Hypotheses 76 (2011) 97-99
30. Habba SF, Am J Gastroenterol 2000;95:8
31. ACG Clinical Guidline: management of irritable bowel syndrome. Lacy, Brian E, Pimentel M, Brenne D et al. Am J Gastroenterol 2021;116: p17-44
32. Camilleri M, Vijayvargiya P, Am J Gastroenterol 2020;115: issue 10-p1596-1603
33. Habba SF, Scand J Gastroenterol, 2012; 47:122-123
2. Drossman DA, Corazziari E, Talley NJ, Whitehead WE, Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology, and treatment. A multi-national consensus. 2nd edition. McLean VA Dagnon associates 2000
3. Boyce PM, Koloski NA, Talley NJL. Irritable bowel syndrome according to varying diagnostic criteria. Is the new Rome to criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2009; 95:3176
4. Peery AF, Dellon ES, Lund J, et al, Burden of gastrointestinal disease in the United States 2012 update. Gastroenterology 2012:143:1179
5. Creed F, Ratcliffe J, Fernandez L, et al. Health related quality of life and healthcare costs and severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 860–8
6. Dean BB, Anguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life and patience with IBS. Am J Manag Care 2005:11S17-26
7. Blake MR, Raker JM, Wheelan K, Validity, and reliability of the Bristol stool form scale in healthy adults and patience with diarrhea predominant irritable bowel syndrome. Ailment Pharmacol Ther 2016; 44:693
8. Schiller, L . Am J Gastroenterol 2018; Volume113-issue 5: p660-669
9. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130;1480
10. Mearin F, Lacy BE, Chang L et al. Bowel Disorders Gastroenterology 2016;150:1393-407
11. Ford AC, Lacy BE, Talley NJ, irritable bowel syndrome. N Eng J Med 2017; 376:2566-78
12. Ford AC, Moayyedi P, Lacy BE, et al. American College of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 (Suppl 1): S2-26
13. McKenzi YA, Alder A,Anderson W,et al. Are British dietetic Association evidence-based guidelines for the dietary management of her irritable bowel syndrome in adults. J Hum Nutr Diet 2012; 25:260
14. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms and irritable bowel syndrome. J Gastronterol Hepatol 2010;25:1366
15. Austin GL, Dalton CB,Hu Y, etal. A very low carbohydrate diet improves symptoms and quality of life in diarrhea predominant irritable bowel syndrome. Clin Gastroenterol Heptol 2009; 7:706
16. Rao SS, Yu S, Fedewa A, A systemic review: dietary fiber and FODMAP-restricted are diet in the management of constipation and a double bowel syndrome. Aliment Pharmacol Ther 2015; 41:1256
17. Eswan SL, Chey WD, Han-Markey T, et al. Randomized controlled trial comparing the low FODMAP diet VS modified NICE guidelines in the US adults with IBS D. Am J Gastroenterol 2016;111:1824
18. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012;345: e5836
19. Zighelboim J,Talley NJ, Phillips SF, et al . Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and Serotonin type 3 antagonism. Dig Dis Sci 1995; 40:819
20. Prior A,Read NW. Reduction of rectal sensitivity and post prandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175
21. Grehon MD, Seratonin and its implications for the management of irritable bowel syndrome. Gastroenterol Disord 2003;3 suppl 2: S25
22. Vasquez-Rofque MI, Camilleri M, Smyrk T et al, a controlled trial of gluten-free diet and patience with irritable bowel syndrome diarrhea effects on bowel frequency and intestinal function. Gastroenterology 2013; 144:903
23. Ruepert L,Quartero AO, deWit NJ, et al, bulking agents and antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; CD 003460
24. Gorard DA, LibbyGW, Farthing MJ. Effect of tricyclic antidepressants on small intestinal motility in health and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86
25. Bueno Fioramonti J,Delvaux M et al, Mediators and pharmacology of visceral sensitivity from basic to clinical investigations. Gastroenterology 1997; 1121:1714
26. American College of gastroenterology task force on irritable bowel syndrome. Brandt LJ, Chey WD, et al. An evidence-based position statement on management of irritable bowel syndrome. Am J Gastroenterol 2009;104suppl 1: S1
27. Multicenter randomized controlled trial. Clin Gastroenterol Hepatol 2015; 13:1285
28. Menees SB, Maneerattannaporn M, Kim HM et al. The efficacy and safety of Rifaximin for the irritable bowel syndrome; a systematic review and meta-analysis. Am J Gastroenterol 2012; 107:28
29. Habba SF, Med Hypotheses 76 (2011) 97-99
30. Habba SF, Am J Gastroenterol 2000;95:8
31. ACG Clinical Guidline: management of irritable bowel syndrome. Lacy, Brian E, Pimentel M, Brenne D et al. Am J Gastroenterol 2021;116: p17-44
32. Camilleri M, Vijayvargiya P, Am J Gastroenterol 2020;115: issue 10-p1596-1603
33. Habba SF, Scand J Gastroenterol, 2012; 47:122-123